MORPHOLOGICAL FEATURES OF THE MYOCARDIUM IN HYPERHOMOCYSTHINEMIA ON THE BACKGROUND OF THYROID DISORDERS

Nechiporuk V. M., Pentyuk L. O., Korda M. M.

MORPHOLOGY

Scentific article

Cardiovascular diseases are the leading cause of death worldwide. It is known that thyroid hormones regulate metabolism in all organs, including the myocardium. Hyperhomocysteinemia (HHCy) is well known as an independent predictor of cardiovascular disease. The aim – to define the reorganization of the structural components of the myocardium under conditions influence of HHCy against the background of hyper- and hypothyroidism. Object and methods. HHCy was modeled by administering exogenous HCy to animals in the form of thiolactone at a dose of 100 mg/kg of body weight once a day for 28 days. Hyperthyroidism (intragastric L-thyroxine for 21 days 200 µg/ kg*day), hypothyroidism (thiamazole 10 kg*day) for 21 days. Separate groups of animals were injected with L-thyroxine and thiamazole in parallel with HCy.Study results. HHCy was accompanied by destructive changes in the myocardium of rats. Violations of vascularization in the vessels were established, erythrocyte stasis and thrombosis were detected. Among the cardiomyocytes of muscle fibers, intercellular edema, destruction and plasmolysis were established. Animals with hyperthyroidism showed signs of vascular insufficiency in the organ. Established uneven blood supply to the vessels of the myocardium. Perivascular and diapedetic hemorrhages, stratification of muscle fibers was detected. Animals with hypertypiosis and HHCy showed an increase in destructive changes in the muscle and connective tissue components of the organ. Rats with hypothyroidism had hemodynamic disturbances in the myocardium, which were manifested by the expansion and blood filling of the vessels of the venous bed, erythrostasis, perivascular edema, local leukocyte infiltration of the interstitium, and an increase in the relative volume of the connective tissue. The combined effect of hypothyroidism and HHCy led to more pronounced degenerative and atrophic changes in the organ wall against the background of significant vascular disorders. Conclusions. Experimental HHCy, hyper- and hypothyroidism in the myocardium of rats, significant microscopic changes in the stromal-vascular-parenchymal components of the organ are observed. Against the background of vascular disorders and increased permeability of the walls of blood vessels, edema of the amorphous component of the interstitial and perivascular connective tissue occurs with the formation of extravasal histoleukocytic infiltrates. Remodeling of cardiomyocyte fibers is manifested by contracture changes, their fragmentation, and intracellular myocytolysis. Under conditions of the combined action of hyperthyroidism and HHCy and hypothyroidism and HHCy, even more pronounced necrotic and degenerative changes in cardiomyocytes occurring against the background of vascular insufficiency in the organ were established: damage to the vascular wall is manifested by hemorrhages and leukocyte inflammatory infiltrates. fibers, significant myocytolysis of cardiomyocytes with stratification and lysis of myofibrils.

hyperthyroidism, hypothyroidism, hyperhomocysteinemia, myocardium.

1. Peng YP, Huang MY, Xue YJ, Pan JL, Lin C. Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention. Biomed Res Int. 2020 Jan 2;2020:1710452. DOI: 10.1155/2020/1710452.
2. Stangl GI, Weisse K, Dinger C, Hirche F, Brandsch C, Eder K. Homocysteine thiolactone-induced hyperhomocysteinemia does not alter concentrations of cholesterol and SREBP-2 target gene mRNAS in rats. Exp Biol Med (Maywood). 2007 Jan;232(1):81-7.
3. Vargas-Uricoechea H, Bonelo-Perdomo A, Sierra-Torres CH. Effects of thyroid hormones on the heart. Clin Investig Arterioscler. 2014;26(6):296-309. DOI: 10.1016/j.arteri.2014.07.003.
4. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020 Jan 1;41(1):12-85. DOI: 10.1093/eurheartj/ehz859.
5. Agoston-Coldea L, Mocan T, Gatfosse M, Lupu S, Dumitrascu DL. Plasma homocysteine and the severity of heart failure in patients with previous myocardial infarction. Cardiol J. 2011;18(1):55-62.
6. He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis. 2014 Nov;24(11):1158-65. DOI: 10.1016/j.numecd.2014.05.011.
7. Han L, Wu Q, Wang C, Hao Y, Zhao J, Zhang L, et al. Homocysteine, Ischemic Stroke, and Coronary Heart Disease in Hypertensive Patients: A Population-Based, Prospective Cohort Study. Stroke. 2015 Jul;46(7):1777-86. DOI: 10.1161/STROKEAHA.115.009111.
8. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012 Sep;122(9):3035-43. DOI: 10.1172/JCI60047.
9. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29(7):898-938. DOI: 10.1210/er.2008-0019.
10. Biegelmeyer E, Scanagata I, Alves L, Reveilleau M, Schwengber FP, Wajner SM. T3 as predictor of mortality in any cause non-critically ill patients. Endocr Connect. 2021 Jul 28;10(8):852-860. DOI: 10.1530/EC-21-0080.
11. Pingitore A, Chen Y, Gerdes AM, Iervasi G. Acute myocardial infarction and thyroid function: new pathophysiological and therapeutic perspectives. Ann Med. 2012 Dec;44(8):745-57. DOI: 10.3109/07853890.2011.573501.
12. Lin YH, Lin KH, Yeh CT. Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance. Front Med (Lausanne). 2020 May 22;7:174. DOI: 10.3389/fmed.2020.00174.
13. Horalʹsʹkyy LP, Khomych VT, Kononsʹkyy OI. Osnovy histolohichnoyi tekhniky i morfofunktsionalʹni metody doslidzhenʹ u normi ta pry patolohiyi. 2 vyd. Zhytomyr: “Polissya”; 2011. 288 s. [in Ukrainian].
14. Nykonenko OS, Chmulʹ KO, Nykonenko AO, Osaulenko VV, Yefymen NF. Prohnostychne znachennya rivniv homotsysteyinu ta vitaminu D u khvorykh na IKHS i mulʹtyfokalʹnyy ateroskleroz. Zaporizʹkyy medychnyy zhurnal. 2018;20(1):31-35. DOI: https://doi.org/10.14739/23 101210.2018.1.121880. [in Ukrainian].
15. Yeh JK, Chen CC, Hsieh MJ, Tsai ML, Yang CH, Chen DY, et al. Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting. J Atheroscler Thromb. 2017 Jul 1;24(7):696-705. DOI: 10.5551/jat.36434.
16. Peng HY, Man CF, Xu J, Fan Y. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B. 2015 Jan;16(1):78-86. DOI: 10.1631/jzus.B1400183.
17. Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J Am Coll Cardiol. 2008 Sep 30;52(14):1152-9. DOI: 10.1016/j.jacc.2008.07.009.
18. Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015 Sep;4(3):149-63. DOI: 10.1159/000438750.
19. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010 Aug;6(8):431-43. DOI: 10.1038/nrendo.2010.105.
20. Yeh JK, Chen CC, Hsieh MJ, Tsai ML, Yang CH, Chen DY, et al. Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting. J Atheroscler Thromb. 2017 Jul 1;24(7):696-705. DOI: 10.5551/jat.36434.
21. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005 Aug;26(5):704-28. DOI: 10.1210/er.2003-0033.
22. Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015 Oct 27;132(17):1667-78. DOI: 10.1161/ CIRCULATIONAHA.114.008720.
23. Lisco G, Giagulli VA, Iovino M, Zupo R, Guastamacchia E, De Pergola G, et al. Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine. 2022 Feb;75(2):360-376. DOI: 10.1007/s12020-021-02912-w.
24. Muzaffar R, Khan MA, Mushtaq MH, Nasir M, Khan A, Haq IU, et al. Hyperhomocysteinemia as an Independent Risk Factor for Coronary Heart Disease. Comparison with Conventional Risk Factors. Braz J Biol. 2021 Sep 6;83:e249104. DOI: 10.1590/1519-6984.249104.

«Bulletin of problems biology and medicine» Issue 1 (163), 2022 year, 259-265 pages, index UDK 577.1:661.29:577.112.3:599.323.4

10.29254/2077-4214-2022-1-163-259-265